Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres.

Knauf, W.U., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2012.

Blood 120(21), 3666.

Studie: TLN; Indikation: Hämoblastosen; Jahr: 2012; Veranstaltung: ASH; Journal: Blood

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com